Tallac Therapeutics

Did you see our feature in this BioSpace article? In this piece, Hong I. Wan, CEO of Tallac Therapeutics, discusses the features of Tallac’s TAC-001, a TLR9 agonist ADC, and how it could potentially benefit a broader patient population with increased safety and tolerability. Read the full article here: https://lnkd.in/gi779jJu https://lnkd.in/gkWcfTXt

Clarivate for Life Sciences & Healthcare highlights Tallac Therapeutics as one of the seven Companies to Watch that are revolutionizing antibody drug conjugates (ADCs). https://lnkd.in/gpCVzZGy

We're excited to share that Hong I. Wan, our President, CEO, and Co-founder, will be speaking at the STING & TLR-Targeted Therapies Summit, hosted by Hanson Wade, on June 19th in San Diego, CA. Hong will present the scientific rationale behind TAC-001, outlining the ongoing TAC-001 phase ½ clinical trial for advanced or metastatic solid tumors and delving into the potential of Tallac Therapeutics' novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform for systemically administered immune agonist conjugates. Find out more: https://lnkd.in/gcZiDPn3 #STING #TLRtargetedtherapies #cancerresearch #immunotherapy #immunooncology

Tallac Therapeutics announces FDA clearance of Investigational New Drug (IND) Application for ALTA-002, a SIRPα targeting Toll-like Receptor Agonist Antibody Conjugate (TRAAC) in patients with advanced solid tumors. ALTA-002 is the second clinical stage program using Tallac’s TRAAC platform.

Tallac Therapeutics is presenting preclinical proof of concept data that will expand the prospective therapeutic application of TAC-001 in oncology and other disease indications. Read our press release: https://lnkd.in/gWZmBHXJ

Join us at #AACR2024 on Wednesday, April 10th, for an exclusive glimpse into the latest immunooncology research! 🧬 We will present preclinical data on Toll-like Receptor Agonist Antibody Conjugate TAC-001 in combination with cancer vaccines, demonstrating TAC-001 potentiates vaccine efficacy and rejuvenates vaccine responses in the elderly.    #immunology #cancervaccines #antibody #aging #immunerejuvenation #antibody #ADC

Join us on the afternoon of November 13th (2 PM EST) at the ACT Meeting Symposium. #ACTOX2023   Vice President of Preclinical Development at Tallac Therapeutics, Bora Han, PhD, DABT, will be presenting preclinical development strategy and insight into the translation of the mechanism of action (MOA) of our novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform. TRAAC delivers a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Find out more: https://lnkd.in/e2BRiVYV

We look forward to joining the #immunooncology community at this year’s #SITC2023 conference to present data for two of our first-in-class toll-like receptor 9 (TLR9) agonist antibody conjugates. TAC-001 is an investigational, systemically delivered, antibody-oligonucleotide conjugate comprised of a potent TLR9 Agonist conjugated to a CD22 antibody, designed to selectively activate B cells to drive an anti-tumor immune response. The findings presented in the TAC-001 poster demonstrate that single-agent TAC-001 is well tolerated, demonstrates pharmacodynamic activity consistent with its proposed MOA, and resulted in preliminary clinical activity with patients achieving durable, stable disease (≥6 months) and partial response per RECIST v1.1. We also presented preclinical data for our Nectin-4 targeted TLR9 agonist antibody conjugate - Tallac’s third TRAAC molecule in the pipeline - demonstrating effective immune cell activation and anti-tumor response. Read more: https://lnkd.in/gsDxgg9e

Join our session on Wednesday, October 11th, where we will introduce you to Tallac's platform of immune-targeted TLR9 agonist antibody conjugates, and TAC-001, a B-cell targeted TLR9 agonist antibody conjugate, that triggers innate and adaptive anti-cancer immunity and is currently a in Phase 1 oncology clinical trial. We will present preclinical evidence of the therapeutic potential of combining TAC-001 with cancer vaccines.